Lineage Cell Therapeutics Stock Filter Stocks by Fundamentals
LCTX Stock | USD 0.61 0 0.23% |
Lineage Cell Therapeutics fundamentals help investors to digest information that contributes to Lineage Cell's financial success or failures. It also enables traders to predict the movement of Lineage Stock. The fundamental analysis module provides a way to measure Lineage Cell's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lineage Cell stock.
Lineage | Cash and Equivalents |
Did you try this?
Run Premium Stories Now
Premium StoriesFollow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
All Next | Launch Module |
Lineage Fundamentals
Return On Equity | -0.35 | ||||
Return On Asset | -0.13 | ||||
Operating Margin | (4.17) % | ||||
Current Valuation | 102.13 M | ||||
Shares Outstanding | 220.42 M | ||||
Shares Owned By Insiders | 0.44 % | ||||
Shares Owned By Institutions | 50.56 % | ||||
Number Of Shares Shorted | 15.94 M | ||||
Price To Earning | 3.62 X | ||||
Price To Book | 2.00 X | ||||
Price To Sales | 21.64 X | ||||
Revenue | 8.95 M | ||||
Gross Profit | 13.97 M | ||||
EBITDA | (24.04 M) | ||||
Net Income | (21.49 M) | ||||
Cash And Equivalents | 66.36 M | ||||
Cash Per Share | 0.39 X | ||||
Total Debt | 2.95 M | ||||
Debt To Equity | 0.04 % | ||||
Current Ratio | 3.01 X | ||||
Book Value Per Share | 0.36 X | ||||
Cash Flow From Operations | (28.57 M) | ||||
Short Ratio | 35.21 X | ||||
Earnings Per Share | (0.10) X | ||||
Target Price | 4.83 | ||||
Number Of Employees | 68 | ||||
Beta | 1.28 | ||||
Market Capitalization | 133.88 M | ||||
Total Asset | 101.02 M | ||||
Retained Earnings | (384.86 M) | ||||
Working Capital | 20.48 M | ||||
Current Asset | 12.84 M | ||||
Current Liabilities | 2.74 M | ||||
Net Asset | 101.02 M |
About Lineage Cell Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lineage Cell Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lineage Cell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lineage Cell Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Lineage Stock Analysis
When running Lineage Cell's price analysis, check to measure Lineage Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lineage Cell is operating at the current time. Most of Lineage Cell's value examination focuses on studying past and present price action to predict the probability of Lineage Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lineage Cell's price. Additionally, you may evaluate how the addition of Lineage Cell to your portfolios can decrease your overall portfolio volatility.